Cost effectiveness of bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) for the first-line treatment of mantle cell lymphoma not eligible for stem cell transplantation: A Scottish perspective

Authors:

van Keep M, Gairy K, Seshagiri D, Thilakarathne P and Lee D.

Publication Type:

Conference Proceedings – Poster

Publication Name:

18th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress

Citation:

van Keep M, Gairy K, Seshagiri D, Thilakarathne P and Lee D. Cost effectiveness of bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) for the first-line treatment of mantle cell lymphoma not eligible for stem cell transplantation: A Scottish perspective. 18th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Milan, Italy. 7- 11 November 2015. Poster PCN131


Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies